EKF Diagnostics (EKF) H1 2026 TU earnings summary

Executive summary

• Trading in H1 2026 was in line with management expectations, with improved gross margin, adjusted EBITDA growth, and continued cash generation.

• Revenue remained broadly flat at £25.0m compared to £25.2m in H1 2025, with a higher weighting of sales expected in H2.

• The five-year strategic plan is progressing as expected, with steady performances in Diabetes and Hematology and strong growth in Life Sciences.

Financial highlights

• Revenue for H1 2026 was £25.0m, nearly unchanged from £25.2m in H1 2025.

• Gross margin improved to 53% from 50% in H1 2025.

• Adjusted EBITDA continued to grow, though the exact figure was not disclosed.

• Cash balance at 30 June 2026 was £16.0m, up from £15.8m at 31 December 2025.

Outlook and guidance

• On track to deliver FY 2026 revenue and adjusted EBITDA growth in line with market expectations (£54.7m revenue, £13.6m adjusted EBITDA).

• Majority of high-volume tenders in Diabetes and Hematology scheduled for delivery in H2, which is historically stronger.